Global Nonalcoholic Steatohepatitis Market

Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2021

Global Nonalcoholic Steatohepatitis Market

Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2021

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

Research Predicts that Nonalcoholic Steatohepatitis (NASH) Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.

Global Nonalcoholic Steatohepatitis (NASH) Market Overview:

Global Nonalcoholic Steatohepatitis (NASH) Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Nonalcoholic Steatohepatitis (NASH) involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

Impact of COVID-19 on Nonalcoholic Steatohepatitis (NASH) Market

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Nonalcoholic Steatohepatitis (NASH) market in 2020.

Global Nonalcoholic Steatohepatitis (NASH) Market Segmentation

By Type, Nonalcoholic Steatohepatitis (NASH) market has been segmented into:

Weight Loss Treatment

Insulin-Sensitizing Agents

Lipid-Lowering Drugs

Antioxidants

Others

By Application, Nonalcoholic Steatohepatitis (NASH) market has been segmented into:

Hospitals

Clinics

Research Institute

Others

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Top Key Players Covered in Nonalcoholic Steatohepatitis (NASH) market are:

Boehringer Ingelheim

Cerenis Therapeutics

Connexios Life Sciences

Genfit

Islet Sciences

Nimbus Therapeutics

Verva Pharmaceuticals

Viking Therapeutics

Astazeneca Plc

Galmed Pharmaceuticals

GENFIT SA

Gilead Science

Novo Nordisk

Immuron

Intercepts Pharmaceuticals

Enzo Biochem

Tobira Therapeutics

1. Market Overview of Nonalcoholic Steatohepatitis (NASH)

1.1 Nonalcoholic Steatohepatitis (NASH) Market Overview

1.1.1 Nonalcoholic Steatohepatitis (NASH) Product Scope

1.1.2 Market Status and Outlook

1.2 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions: 2015 VS 2021 VS 2026

1.3 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Regions (2015-2020)

1.4 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Regions (2021-2026)

1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)

1.5.1 North America

1.5.2 East Asia

1.5.3 Europe

1.5.4 South Asia

1.5.5 Southeast Asia

1.5.6 Middle East

1.5.7 Africa

1.5.8 Oceania

1.5.9 South America

1.5.10 Rest of the World

1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.6.2 Covid-19 Impact: Commodity Prices Indices

1.6.3 Covid-19 Impact: Global Major Government Policy

2. Covid-19 Impact Nonalcoholic Steatohepatitis (NASH) Sales Market by Type (2015-2026)

2.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2015-2020)

2.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2021-2026)

2.3 Weight Loss Treatment

2.4 Insulin-Sensitizing Agents

2.5 Lipid-Lowering Drugs

2.6 Antioxidants

2.7 Others

3. Covid-19 Impact Nonalcoholic Steatohepatitis (NASH) Sales Market by Application (2015-2026)

3.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2015-2020)

3.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2021-2026)

3.3 Hospitals

3.4 Clinics

3.5 Research Institute

3.6 Others

4. Covid-19 Impact Market Competition by Manufacturers

4.1 Global Nonalcoholic Steatohepatitis (NASH) Production Capacity Market Share by Manufacturers (2015-2020)

4.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2015-2020)

4.3 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2015-2020)

5. Company Profiles and Key Figures in Nonalcoholic Steatohepatitis (NASH) Business

5.1 Boehringer Ingelheim

5.1.1 Boehringer Ingelheim Company Profile

5.1.2 Boehringer Ingelheim Nonalcoholic Steatohepatitis (NASH) Product Specification

5.1.3 Boehringer Ingelheim Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.2 Cerenis Therapeutics

5.2.1 Cerenis Therapeutics Company Profile

5.2.2 Cerenis Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification

5.2.3 Cerenis Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.3 Connexios Life Sciences

5.3.1 Connexios Life Sciences Company Profile

5.3.2 Connexios Life Sciences Nonalcoholic Steatohepatitis (NASH) Product Specification

5.3.3 Connexios Life Sciences Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.4 Genfit

5.4.1 Genfit Company Profile

5.4.2 Genfit Nonalcoholic Steatohepatitis (NASH) Product Specification

5.4.3 Genfit Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.5 Islet Sciences

5.5.1 Islet Sciences Company Profile

5.5.2 Islet Sciences Nonalcoholic Steatohepatitis (NASH) Product Specification

5.5.3 Islet Sciences Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.6 Nimbus Therapeutics

5.6.1 Nimbus Therapeutics Company Profile

5.6.2 Nimbus Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification

5.6.3 Nimbus Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.7 Verva Pharmaceuticals

5.7.1 Verva Pharmaceuticals Company Profile

5.7.2 Verva Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification

5.7.3 Verva Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.8 Viking Therapeutics

5.8.1 Viking Therapeutics Company Profile

5.8.2 Viking Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification

5.8.3 Viking Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.9 Astazeneca Plc

5.9.1 Astazeneca Plc Company Profile

5.9.2 Astazeneca Plc Nonalcoholic Steatohepatitis (NASH) Product Specification

5.9.3 Astazeneca Plc Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.10 Galmed Pharmaceuticals

5.10.1 Galmed Pharmaceuticals Company Profile

5.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification

5.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.11 GENFIT SA

5.11.1 GENFIT SA Company Profile

5.11.2 GENFIT SA Nonalcoholic Steatohepatitis (NASH) Product Specification

5.11.3 GENFIT SA Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.12 Gilead Science

5.12.1 Gilead Science Company Profile

5.12.2 Gilead Science Nonalcoholic Steatohepatitis (NASH) Product Specification

5.12.3 Gilead Science Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.13 Novo Nordisk

5.13.1 Novo Nordisk Company Profile

5.13.2 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Specification

5.13.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.14 Immuron

5.14.1 Immuron Company Profile

5.14.2 Immuron Nonalcoholic Steatohepatitis (NASH) Product Specification

5.14.3 Immuron Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.15 Intercepts Pharmaceuticals

5.15.1 Intercepts Pharmaceuticals Company Profile

5.15.2 Intercepts Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Specification

5.15.3 Intercepts Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.16 Enzo Biochem

5.16.1 Enzo Biochem Company Profile

5.16.2 Enzo Biochem Nonalcoholic Steatohepatitis (NASH) Product Specification

5.16.3 Enzo Biochem Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

5.17 Tobira Therapeutics

5.17.1 Tobira Therapeutics Company Profile

5.17.2 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Specification

5.17.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Production Capacity, Revenue, Price and Gross Margin (2015-2020)

6. North America

6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

6.2 North America Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

7. East Asia

7.1 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

7.2 East Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

7.3 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

7.4 East Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

8. Europe

8.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

8.2 Europe Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

8.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

8.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

9. South Asia

9.1 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

9.2 South Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

9.3 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

9.4 South Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

10. Southeast Asia

10.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

10.2 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

10.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

10.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

11. Middle East

11.1 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

11.2 Middle East Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

11.3 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

11.4 Middle East Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

12. Africa

12.1 Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

12.2 Africa Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

12.3 Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

12.4 Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

13. Oceania

13.1 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

13.2 Oceania Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

13.3 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

13.4 Oceania Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

14. South America

14.1 South America Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

14.2 South America Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

14.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

14.4 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

15. Rest of the World

15.1 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size (2015-2026)

15.2 Rest of the World Nonalcoholic Steatohepatitis (NASH) Key Players in North America (2015-2020)

15.3 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2015-2020)

15.4 Rest of the World Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2015-2020)

16 Nonalcoholic Steatohepatitis (NASH) Market Dynamics

16.1 Covid-19 Impact Market Top Trends

16.2 Covid-19 Impact Market Drivers

16.3 Covid-19 Impact Market Challenges

16.4 Porter’s Five Forces Analysis

18 Regulatory Information

17 Analyst's Viewpoints/Conclusions

18 Appendix

18.1 Research Methodology

18.1.1 Methodology/Research Approach

18.1.2 Data Source

18.2 Disclaimer

Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Nonalcoholic Steatohepatitis (NASH) Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
Who are the dominant players having a strong presence in the Nonalcoholic Steatohepatitis (NASH) Market?
Some of the finest and top-notch companies pioneering the Nonalcoholic Steatohepatitis (NASH) Market are Boehringer Ingelheim, Cerenis Therapeutics, Connexios Life Sciences, Genfit, Islet Sciences, Nimbus Therapeutics, Verva Pharmaceuticals, Viking Therapeutics, Astazeneca Plc, Galmed Pharmaceuticals, GENFIT SA, Gilead Science, Novo Nordisk, Immuron, Intercepts Pharmaceuticals, Enzo Biochem, Tobira Therapeutics.
What is the major concern of the players in the Nonalcoholic Steatohepatitis (NASH) Market?
As manufacturers prepare to scale up, Nonalcoholic Steatohepatitis (NASH) companies must be clear and transparent about the impact of such volatility on the balance sheet.
What are the major applications for Nonalcoholic Steatohepatitis (NASH)?
Nonalcoholic Steatohepatitis (NASH) has a wide range of applications, including and others.
What is the expected rate of growth in the Nonalcoholic Steatohepatitis (NASH) Market?
From 2025 to 2030, the Nonalcoholic Steatohepatitis (NASH) Market is expected to grow at a compound annual growth rate of YY%, reaching a value of USD XXX Million.
In the current situation, what value does the Nonalcoholic Steatohepatitis (NASH) Market have?
The value of the Nonalcoholic Steatohepatitis (NASH) Market is estimated to be USD XXX million.
What makes the latest Nonalcoholic Steatohepatitis (NASH) Market study unique?
The latest version of the Nonalcoholic Steatohepatitis (NASH) Market study includes a market size breakdown by relevant business segments, applications, and geography, as well as qualitative insights such as Patent Analysis*, Market Entropy, Key Development Activities, Market Dynamics, PEST and PORTER models, and more.